Symbols

GILD

Gilead Sciences·NASDAQ

--(--)

GILD fundamentals

GILD Q4 2025 Earnings

Gilead Sciences (GILD) released its earnings on Feb 10, 2026: revenue was 7.92B (YoY +4.70%), beat estimates; EPS was 1.86 (YoY -2.11%), beat estimates.

Revenue / YoY

7.92B

+4.70%

EPS / YoY

1.86

-2.11%

Report date

Feb 10, 2026

GILD Earnings Call Summary for Q4,2025

HIV Dominance: 2025 HIV sales up 6% to $20.8 billion, with Yeztugo on track for $800 million in 2026.
Liver Leadership: Livdelzi captures 50% U.S. market share in second-line PBC, driving 6% liver business growth.
Oncology Breakthrough: Trodelvy poised for first-line TNBC approval in 2026, supported by 15-month OS in Phase II trial.
Pipeline Power: 4 potential 2026 launches and 5 Phase III readouts position Gilead for sustained growth.
Financial Strength: 2026 guidance for $29.6-30 billion in sales, 87% gross margin, and $8.45-8.85 EPS, with disciplined expense management.

Earnings

EPS

Revenue

Revenue & Expenses

GILD has released its 2025 Q4 earnings report, with revenue of 7.92B, reflecting a YoY change of 4.70%, and net profit of 2.18B, showing a YoY change of 22.43%. The Sankey diagram below clearly presents GILD's revenue sources and cost distribution.

Key Indicators

Gilead Sciences (GILD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Gilead Sciences (GILD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Gilead Sciences (GILD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Gilead Sciences (GILD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown